Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Exelixis
Incyte Corporation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Washington University School of Medicine
Washington University School of Medicine
City of Hope Medical Center
Stanford University
Milton S. Hershey Medical Center
Columbia University
St. Joseph's Hospital and Medical Center, Phoenix
Wake Forest University Health Sciences
Mayo Clinic
University of Alabama at Birmingham
City of Hope Medical Center
Alaunos Therapeutics
National Institutes of Health Clinical Center (CC)
University of Alabama at Birmingham
Jazz Pharmaceuticals
Istari Oncology, Inc.
Hackensack Meridian Health
Mayo Clinic
Washington University School of Medicine
BioMimetix JV, LLC
St. Joseph's Hospital and Medical Center, Phoenix
Washington University School of Medicine
University of Oklahoma
Thomas Jefferson University
Children's Hospital Medical Center, Cincinnati
Regeneron Pharmaceuticals
Servier
University of Pittsburgh
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, San Francisco
Children's Oncology Group
University of Florida
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
Massachusetts General Hospital
Washington University School of Medicine
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dana-Farber Cancer Institute
Virginia Commonwealth University